S84 Identification of MIR-124a as a major regulator of enhanced endothelial cell glycolysis in pulmonary arterial hypertension

IntroductionPulmonary arterial hypertension (PAH) is a rare desease characterised by profound vascular abnormalities in the peripheral arteries of the lung, leading to a progressive increase in pulmonary vascular resistance, right heart failure and death. The disease exists in several forms includin...

Full description

Saved in:
Bibliographic Details
Published in:Thorax 2016-12, Vol.71 (Suppl 3), p.A48-A49
Main Authors: Caruso, P, Dunmore, BJ, Schlosser, K, Schoors, S, Santos, C Dos, Perez-Iratxeta, C, Lavoie, JR, Long, L, Hurst, L, Ormiston, ML, Hata, A, Carmeliet, P, Stewart, DJ, Morrell, NW
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b2260-12e8b87d60629a67da22164306aa1fbdd11b16dc07c329c406fe113ab1af56773
cites
container_end_page A49
container_issue Suppl 3
container_start_page A48
container_title Thorax
container_volume 71
creator Caruso, P
Dunmore, BJ
Schlosser, K
Schoors, S
Santos, C Dos
Perez-Iratxeta, C
Lavoie, JR
Long, L
Hurst, L
Ormiston, ML
Hata, A
Carmeliet, P
Stewart, DJ
Morrell, NW
description IntroductionPulmonary arterial hypertension (PAH) is a rare desease characterised by profound vascular abnormalities in the peripheral arteries of the lung, leading to a progressive increase in pulmonary vascular resistance, right heart failure and death. The disease exists in several forms including a heritable form (HPAH) caused primarily by mutations in bone morphogenetic protein receptor type 2 (BMPR2) and an idiopathic form (IPAH). Endothelial cell (EC) dysfunction is considered a critical initiating factor in the pathobiology of PAH, manifested by increased susceptibility to apoptosis, heightened permeability and enhanced endothelial proliferation. Substantial changes in bioenergetics of ECs, including higher rates of glycolysis, have been reported in PAH patients. However, the mechanisms underlying alterations in energy production have not been identified.MethodsWe measured glycolysis in blood outgrowth endothelial cells (BOECs) from HPAH patients carrying mutations in BMPR2 and IPAH patients to confirm the metabolic abnormalities previously. We also employed an unbiased genome-wide microarray and proteomic screening approach to detect miRNAs and proteins dysregulated in the same groups to determine the mechanisms underlying abnormal endothelial glycolysis.ResultsHPAH and IPAH BOECs recapitulated the metabolic phenotype previously observed in PAECs. These alterations were found to be associated with the downregulation of miR-124 and the upregulation of its known target, splicing factor polypyrimidine-tract-binding protein (PTBP1). We also demonstrated that increased PTBP1 promotes the switching in expression of two forms of pyruvate kinase, PKM1 and PKM2, resulting in an increase of aerobic glycolysis, consequently increasing cell proliferation (mechanism schematized in Figure 1). Overexpression of miR-124, or siRNA silencing of PTPB1, restoring normal expression levels of PKM2, also restored normal proliferation and glycolysis in HPAH BOECs. Finally, we observed reduced miR-124 and increased PTPB1 and PKM2 expression in a well-established rat model of PAH, characterised by endothelial proliferation, supporting the presence of this mechanism in vivo.ConclusionsLoss of function of BMPR2 results in the downregulation of miR-124 and consequently in the glycolytic abnormalities reported in PAH ECs. Therefore, the manipulation of this miRNA, or its targets, could represent a novel and effective strategy to achieve clinical benefits in the treatment of PA
doi_str_mv 10.1136/thoraxjnl-2016-209333.90
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1845245339</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4267701311</sourcerecordid><originalsourceid>FETCH-LOGICAL-b2260-12e8b87d60629a67da22164306aa1fbdd11b16dc07c329c406fe113ab1af56773</originalsourceid><addsrcrecordid>eNqNkMtKxDAUhoMoOI6-Q8B1x1w6abuUwcvAiOBlHU7bdNqSJjVpwe5m44v6JGaouHZzzr_4_3P5EMKUrCjl4maorYPP1uiIESpCyTjnq4ycoAWNRRpxlolTtCAkJpHgiThHF963hJCU0mSBDq9p_H342pbKDE3VFDA01mBb4aftS0RZDBg8BtxBax12aj9qGIIKBmVqMIUqgyjtUCvdgMaF0hrv9VRYPfnG48bgftSdNeAmDG5Q7uiqp14FbXzYdYnOKtBeXf32JXq_v3vbPEa754ft5nYX5YwJEk5RaZ4mpSCCZSCSEhijIuZEANAqL0tKcyrKgiRF-LiIiahU4AM5hWotkoQv0fU8t3f2Y1R-kK0dnQkrJU3jNYvXnGfBlc6uwlnvnapk75ouHC8pkUfe8o-3PPKWM2-ZkRDlczTv2v-nfgB9wYj5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1845245339</pqid></control><display><type>article</type><title>S84 Identification of MIR-124a as a major regulator of enhanced endothelial cell glycolysis in pulmonary arterial hypertension</title><source>Alma/SFX Local Collection</source><creator>Caruso, P ; Dunmore, BJ ; Schlosser, K ; Schoors, S ; Santos, C Dos ; Perez-Iratxeta, C ; Lavoie, JR ; Long, L ; Hurst, L ; Ormiston, ML ; Hata, A ; Carmeliet, P ; Stewart, DJ ; Morrell, NW</creator><creatorcontrib>Caruso, P ; Dunmore, BJ ; Schlosser, K ; Schoors, S ; Santos, C Dos ; Perez-Iratxeta, C ; Lavoie, JR ; Long, L ; Hurst, L ; Ormiston, ML ; Hata, A ; Carmeliet, P ; Stewart, DJ ; Morrell, NW</creatorcontrib><description>IntroductionPulmonary arterial hypertension (PAH) is a rare desease characterised by profound vascular abnormalities in the peripheral arteries of the lung, leading to a progressive increase in pulmonary vascular resistance, right heart failure and death. The disease exists in several forms including a heritable form (HPAH) caused primarily by mutations in bone morphogenetic protein receptor type 2 (BMPR2) and an idiopathic form (IPAH). Endothelial cell (EC) dysfunction is considered a critical initiating factor in the pathobiology of PAH, manifested by increased susceptibility to apoptosis, heightened permeability and enhanced endothelial proliferation. Substantial changes in bioenergetics of ECs, including higher rates of glycolysis, have been reported in PAH patients. However, the mechanisms underlying alterations in energy production have not been identified.MethodsWe measured glycolysis in blood outgrowth endothelial cells (BOECs) from HPAH patients carrying mutations in BMPR2 and IPAH patients to confirm the metabolic abnormalities previously. We also employed an unbiased genome-wide microarray and proteomic screening approach to detect miRNAs and proteins dysregulated in the same groups to determine the mechanisms underlying abnormal endothelial glycolysis.ResultsHPAH and IPAH BOECs recapitulated the metabolic phenotype previously observed in PAECs. These alterations were found to be associated with the downregulation of miR-124 and the upregulation of its known target, splicing factor polypyrimidine-tract-binding protein (PTBP1). We also demonstrated that increased PTBP1 promotes the switching in expression of two forms of pyruvate kinase, PKM1 and PKM2, resulting in an increase of aerobic glycolysis, consequently increasing cell proliferation (mechanism schematized in Figure 1). Overexpression of miR-124, or siRNA silencing of PTPB1, restoring normal expression levels of PKM2, also restored normal proliferation and glycolysis in HPAH BOECs. Finally, we observed reduced miR-124 and increased PTPB1 and PKM2 expression in a well-established rat model of PAH, characterised by endothelial proliferation, supporting the presence of this mechanism in vivo.ConclusionsLoss of function of BMPR2 results in the downregulation of miR-124 and consequently in the glycolytic abnormalities reported in PAH ECs. Therefore, the manipulation of this miRNA, or its targets, could represent a novel and effective strategy to achieve clinical benefits in the treatment of PAH.Abstract S84 Figure 1</description><identifier>ISSN: 0040-6376</identifier><identifier>EISSN: 1468-3296</identifier><identifier>DOI: 10.1136/thoraxjnl-2016-209333.90</identifier><identifier>CODEN: THORA7</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><ispartof>Thorax, 2016-12, Vol.71 (Suppl 3), p.A48-A49</ispartof><rights>2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b2260-12e8b87d60629a67da22164306aa1fbdd11b16dc07c329c406fe113ab1af56773</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids></links><search><creatorcontrib>Caruso, P</creatorcontrib><creatorcontrib>Dunmore, BJ</creatorcontrib><creatorcontrib>Schlosser, K</creatorcontrib><creatorcontrib>Schoors, S</creatorcontrib><creatorcontrib>Santos, C Dos</creatorcontrib><creatorcontrib>Perez-Iratxeta, C</creatorcontrib><creatorcontrib>Lavoie, JR</creatorcontrib><creatorcontrib>Long, L</creatorcontrib><creatorcontrib>Hurst, L</creatorcontrib><creatorcontrib>Ormiston, ML</creatorcontrib><creatorcontrib>Hata, A</creatorcontrib><creatorcontrib>Carmeliet, P</creatorcontrib><creatorcontrib>Stewart, DJ</creatorcontrib><creatorcontrib>Morrell, NW</creatorcontrib><title>S84 Identification of MIR-124a as a major regulator of enhanced endothelial cell glycolysis in pulmonary arterial hypertension</title><title>Thorax</title><description>IntroductionPulmonary arterial hypertension (PAH) is a rare desease characterised by profound vascular abnormalities in the peripheral arteries of the lung, leading to a progressive increase in pulmonary vascular resistance, right heart failure and death. The disease exists in several forms including a heritable form (HPAH) caused primarily by mutations in bone morphogenetic protein receptor type 2 (BMPR2) and an idiopathic form (IPAH). Endothelial cell (EC) dysfunction is considered a critical initiating factor in the pathobiology of PAH, manifested by increased susceptibility to apoptosis, heightened permeability and enhanced endothelial proliferation. Substantial changes in bioenergetics of ECs, including higher rates of glycolysis, have been reported in PAH patients. However, the mechanisms underlying alterations in energy production have not been identified.MethodsWe measured glycolysis in blood outgrowth endothelial cells (BOECs) from HPAH patients carrying mutations in BMPR2 and IPAH patients to confirm the metabolic abnormalities previously. We also employed an unbiased genome-wide microarray and proteomic screening approach to detect miRNAs and proteins dysregulated in the same groups to determine the mechanisms underlying abnormal endothelial glycolysis.ResultsHPAH and IPAH BOECs recapitulated the metabolic phenotype previously observed in PAECs. These alterations were found to be associated with the downregulation of miR-124 and the upregulation of its known target, splicing factor polypyrimidine-tract-binding protein (PTBP1). We also demonstrated that increased PTBP1 promotes the switching in expression of two forms of pyruvate kinase, PKM1 and PKM2, resulting in an increase of aerobic glycolysis, consequently increasing cell proliferation (mechanism schematized in Figure 1). Overexpression of miR-124, or siRNA silencing of PTPB1, restoring normal expression levels of PKM2, also restored normal proliferation and glycolysis in HPAH BOECs. Finally, we observed reduced miR-124 and increased PTPB1 and PKM2 expression in a well-established rat model of PAH, characterised by endothelial proliferation, supporting the presence of this mechanism in vivo.ConclusionsLoss of function of BMPR2 results in the downregulation of miR-124 and consequently in the glycolytic abnormalities reported in PAH ECs. Therefore, the manipulation of this miRNA, or its targets, could represent a novel and effective strategy to achieve clinical benefits in the treatment of PAH.Abstract S84 Figure 1</description><issn>0040-6376</issn><issn>1468-3296</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqNkMtKxDAUhoMoOI6-Q8B1x1w6abuUwcvAiOBlHU7bdNqSJjVpwe5m44v6JGaouHZzzr_4_3P5EMKUrCjl4maorYPP1uiIESpCyTjnq4ycoAWNRRpxlolTtCAkJpHgiThHF963hJCU0mSBDq9p_H342pbKDE3VFDA01mBb4aftS0RZDBg8BtxBax12aj9qGIIKBmVqMIUqgyjtUCvdgMaF0hrv9VRYPfnG48bgftSdNeAmDG5Q7uiqp14FbXzYdYnOKtBeXf32JXq_v3vbPEa754ft5nYX5YwJEk5RaZ4mpSCCZSCSEhijIuZEANAqL0tKcyrKgiRF-LiIiahU4AM5hWotkoQv0fU8t3f2Y1R-kK0dnQkrJU3jNYvXnGfBlc6uwlnvnapk75ouHC8pkUfe8o-3PPKWM2-ZkRDlczTv2v-nfgB9wYj5</recordid><startdate>201612</startdate><enddate>201612</enddate><creator>Caruso, P</creator><creator>Dunmore, BJ</creator><creator>Schlosser, K</creator><creator>Schoors, S</creator><creator>Santos, C Dos</creator><creator>Perez-Iratxeta, C</creator><creator>Lavoie, JR</creator><creator>Long, L</creator><creator>Hurst, L</creator><creator>Ormiston, ML</creator><creator>Hata, A</creator><creator>Carmeliet, P</creator><creator>Stewart, DJ</creator><creator>Morrell, NW</creator><general>BMJ Publishing Group LTD</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201612</creationdate><title>S84 Identification of MIR-124a as a major regulator of enhanced endothelial cell glycolysis in pulmonary arterial hypertension</title><author>Caruso, P ; Dunmore, BJ ; Schlosser, K ; Schoors, S ; Santos, C Dos ; Perez-Iratxeta, C ; Lavoie, JR ; Long, L ; Hurst, L ; Ormiston, ML ; Hata, A ; Carmeliet, P ; Stewart, DJ ; Morrell, NW</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b2260-12e8b87d60629a67da22164306aa1fbdd11b16dc07c329c406fe113ab1af56773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caruso, P</creatorcontrib><creatorcontrib>Dunmore, BJ</creatorcontrib><creatorcontrib>Schlosser, K</creatorcontrib><creatorcontrib>Schoors, S</creatorcontrib><creatorcontrib>Santos, C Dos</creatorcontrib><creatorcontrib>Perez-Iratxeta, C</creatorcontrib><creatorcontrib>Lavoie, JR</creatorcontrib><creatorcontrib>Long, L</creatorcontrib><creatorcontrib>Hurst, L</creatorcontrib><creatorcontrib>Ormiston, ML</creatorcontrib><creatorcontrib>Hata, A</creatorcontrib><creatorcontrib>Carmeliet, P</creatorcontrib><creatorcontrib>Stewart, DJ</creatorcontrib><creatorcontrib>Morrell, NW</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Thorax</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caruso, P</au><au>Dunmore, BJ</au><au>Schlosser, K</au><au>Schoors, S</au><au>Santos, C Dos</au><au>Perez-Iratxeta, C</au><au>Lavoie, JR</au><au>Long, L</au><au>Hurst, L</au><au>Ormiston, ML</au><au>Hata, A</au><au>Carmeliet, P</au><au>Stewart, DJ</au><au>Morrell, NW</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>S84 Identification of MIR-124a as a major regulator of enhanced endothelial cell glycolysis in pulmonary arterial hypertension</atitle><jtitle>Thorax</jtitle><date>2016-12</date><risdate>2016</risdate><volume>71</volume><issue>Suppl 3</issue><spage>A48</spage><epage>A49</epage><pages>A48-A49</pages><issn>0040-6376</issn><eissn>1468-3296</eissn><coden>THORA7</coden><abstract>IntroductionPulmonary arterial hypertension (PAH) is a rare desease characterised by profound vascular abnormalities in the peripheral arteries of the lung, leading to a progressive increase in pulmonary vascular resistance, right heart failure and death. The disease exists in several forms including a heritable form (HPAH) caused primarily by mutations in bone morphogenetic protein receptor type 2 (BMPR2) and an idiopathic form (IPAH). Endothelial cell (EC) dysfunction is considered a critical initiating factor in the pathobiology of PAH, manifested by increased susceptibility to apoptosis, heightened permeability and enhanced endothelial proliferation. Substantial changes in bioenergetics of ECs, including higher rates of glycolysis, have been reported in PAH patients. However, the mechanisms underlying alterations in energy production have not been identified.MethodsWe measured glycolysis in blood outgrowth endothelial cells (BOECs) from HPAH patients carrying mutations in BMPR2 and IPAH patients to confirm the metabolic abnormalities previously. We also employed an unbiased genome-wide microarray and proteomic screening approach to detect miRNAs and proteins dysregulated in the same groups to determine the mechanisms underlying abnormal endothelial glycolysis.ResultsHPAH and IPAH BOECs recapitulated the metabolic phenotype previously observed in PAECs. These alterations were found to be associated with the downregulation of miR-124 and the upregulation of its known target, splicing factor polypyrimidine-tract-binding protein (PTBP1). We also demonstrated that increased PTBP1 promotes the switching in expression of two forms of pyruvate kinase, PKM1 and PKM2, resulting in an increase of aerobic glycolysis, consequently increasing cell proliferation (mechanism schematized in Figure 1). Overexpression of miR-124, or siRNA silencing of PTPB1, restoring normal expression levels of PKM2, also restored normal proliferation and glycolysis in HPAH BOECs. Finally, we observed reduced miR-124 and increased PTPB1 and PKM2 expression in a well-established rat model of PAH, characterised by endothelial proliferation, supporting the presence of this mechanism in vivo.ConclusionsLoss of function of BMPR2 results in the downregulation of miR-124 and consequently in the glycolytic abnormalities reported in PAH ECs. Therefore, the manipulation of this miRNA, or its targets, could represent a novel and effective strategy to achieve clinical benefits in the treatment of PAH.Abstract S84 Figure 1</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/thoraxjnl-2016-209333.90</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0040-6376
ispartof Thorax, 2016-12, Vol.71 (Suppl 3), p.A48-A49
issn 0040-6376
1468-3296
language eng
recordid cdi_proquest_journals_1845245339
source Alma/SFX Local Collection
title S84 Identification of MIR-124a as a major regulator of enhanced endothelial cell glycolysis in pulmonary arterial hypertension
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T23%3A01%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=S84%E2%80%85Identification%20of%20MIR-124a%20as%20a%20major%20regulator%20of%20enhanced%20endothelial%20cell%20glycolysis%20in%20pulmonary%20arterial%20hypertension&rft.jtitle=Thorax&rft.au=Caruso,%20P&rft.date=2016-12&rft.volume=71&rft.issue=Suppl%203&rft.spage=A48&rft.epage=A49&rft.pages=A48-A49&rft.issn=0040-6376&rft.eissn=1468-3296&rft.coden=THORA7&rft_id=info:doi/10.1136/thoraxjnl-2016-209333.90&rft_dat=%3Cproquest_cross%3E4267701311%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b2260-12e8b87d60629a67da22164306aa1fbdd11b16dc07c329c406fe113ab1af56773%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1845245339&rft_id=info:pmid/&rfr_iscdi=true